Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5.F35-hGUCY2C-PADRE and Lm-GUCY2C Vaccines in Advanced Colorectal and Small Bowel Adenocarcinomas
NCT07417488Phase 1Recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Microbiome Therapeutics, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ad5.F35-GUCY2C-PADRE and Lm-GUCY2C in colorectal cancer (CRC) and small bowel adenocarcinoma (SBA) (4 arms), sponsored by Thomas Jefferson University. Primary endpoints: Rate of Dose Limiting Toxicities and Number of patients with dose limiting toxicities. Started Apr 2026; status: recruiting.
02
Drugs
Ad5.F35-GUCY2C-PADRELm-GUCY2C
03
Conditions
colorectal cancer (CRC)small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT07417488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07417488.